PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

• ClinicalTrials.gov Identifier: NCT03069963
• Recruitment Status: Completed
• First Posted: March 3, 2017
• Last Update Posted: May 12, 2022
• Sponsor: Sanofi
• Information provided by (Responsible Party): Sanofi

Study Description

Brief Summary:

Primary Objective:

Pharmacodynamics: assessment by pH metry of the change in gastric pH (antacid activity) of Z0063, in comparison to the effect of Gaviscon Double Action Tablets, in healthy adult subjects.

Secondary Objective:

Safety: assessment of the clinical safety of Z0063, and Gaviscon Double Action Tablets, in healthy adult subjects.

Condition or disease	Intervention/treatment	Phase
Gastroesophageal Reflux Disease	Drug: Z0063; Drug: Gaviscon	Phase 1

Detailed Description:

The maximal total study duration per subject is 5 weeks and 1 day.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: A Randomized, Open Label, 2-Treatment Crossover Study to Compare by pH Metry, the Antacid Activity of the To-be-registered Product (250 mg Sodium Alginate/187.5 mg Calcium Carbonate/106.5 mg Sodium Hydrogen Carbonate, Chewable Tablets) Versus the Registered Gaviscon Double Action Tablets, in Healthy Adult Subject
• Actual Study Start Date: February 24, 2017
• Actual Primary Completion Date: April 23, 2017
• Actual Study Completion Date: April 23, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Sequence 1 (Z0063 to Gaviscon); The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose	Drug: Z0063; Pharmaceutical form: chewable tablets Route of administration: oral; Drug: Gaviscon; Pharmaceutical form: chewable tablets Route of administration: oral
Experimental: Sequence 2 (Gaviscon to Z0063); The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose	Drug: Z0063; Pharmaceutical form: chewable tablets Route of administration: oral; Drug: Gaviscon; Pharmaceutical form: chewable tablets Route of administration: oral

Outcome Measures

Primary Outcome Measures :

1. Percentage of time at which the intragastric pH is at least equal to or greater than 4 during the 4-hour observation period post-dose [ Time Frame: 4 hours after the investigational medicinal product (IMP) administration ]

Secondary Outcome Measures :

1. Percentage of time at which the intragastric pH is at least equal to or greater than 3 during the 4-hour observation period post-dose [ Time Frame: 4 hours after the IMP administration ]
2. 4-hour median pH [ Time Frame: 4 hours after the IMP administration ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion criteria :

• Male or female subjects, between 18 and 55 years of age, inclusive.
• Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 28.0 kg/m2, inclusive.
• Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
• Normal vital signs, electrocardiogram (ECG) and laboratory parameters.
• Subject has to accept a gastric probe.

Exclusion criteria:

• Any history or presence of clinically relevant abnormalities at screening which could interfere with the objectives of the study or the safety of the subject's participation.
• Blood donation, any volume, within 2 months before inclusion.
• History or presence of drug or alcohol abuse.
• Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during the study.
• If female, pregnancy (defined as positive beta-human chorionic gonadotropin [β-HCG] blood test), breast-feeding.
• Any medication (including St John's Wort) within 14 days before inclusion, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion.
• Any subject in the exclusion period of a previous study according to applicable regulations.
• Any subject who cannot be contacted in case of emergency.
• Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).
• Positive result on urine drug screen.
• Positive alcohol breath test.
• Known hypersensitive to alginates, products or formulation excipients, and/or to any component of the standardized meal.
• Any subject with difficulty in chewing and swallowing.
• Any subject with strong gag reflex.
• Any intake of aluminium and magnesium containing antacids or other alginate-containing medicinal products within 14 days before inclusion.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Locations

France

Investigational Site Number 2500001

Gieres, France, 38610

Sponsors and Collaborators

Sanofi

Investigators

• Study Director: Clinical Sciences & Operations; Sanofi

More Information

• Responsible Party: Sanofi
• ClinicalTrials.gov Identifier: NCT03069963
• Other Study ID Numbers: PDY14362; 2015-000763-13 ( EudraCT Number ); U1111-1183-5042 ( Other Identifier: UTN )
• First Posted: March 3, 2017
• Last Update Posted: May 12, 2022
• Last Verified: June 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Gastroesophageal Reflux; Esophageal Motility Disorders; Deglutition Disorders; Esophageal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; Antacids; Molecular Mechanisms of Pharmacological Action; Gastrointestinal Agents